Related Experiment Video
Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
Relationship between amyloid burden, cholinergic integrity, and cognitive function
Li-Hua Lee1, Chia-Ju Chou1, Yao-Chia Shih2
1Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Abstract:
BackgroundAmyloid accumulation and degeneration of the cholinergic white matter pathways are key factors in early Alzheimer's disease pathogenesis and progression. However, the relationship between them remains unclear.ObjectiveTo investigate the association between amyloid accumulation, the integrity of cholinergic white matter pathways, and cognitive performance.MethodsThis cross-sectional study recruited 109 individuals, including 37 controls with normal cognition and 72 patients with early Alzheimer's disease. All participants underwent neuropsychological testing: the Mini-Mental Status Examination (MMSE), Clinical Dementia Rating scale with sum of box (CDR-SB), and verbal fluency tests. Cholinergic white matter integrity and amyloid burden were assessed through diffusion tensor imaging study (DTI) and amyloid positron emission tomography (PET). Stepwise linear regression analyses were performed. Partial correlations between amyloid burden and cholinergic integrity were also evaluated according to apolipoprotein E4 (APOE4) carrier status.ResultsAcross all participants, amyloid burden and cholinergic integrity were independently associated with all cognitive performances. In subgroup analysis, amyloid burden was associated with MMSE only in the early Alzheimer's disease group (p = 0.012). Cholinergic integrity was significantly associated with all cognitive performances in the early Alzheimer's disease group (p < 0.05) but not in the control group. Amyloid burden remained significantly correlated with cholinergic integrity only in APOE4 noncarriers (p < 0.05) but not in APOE4 carriers.ConclusionsCholinergic white matter integrity, the severity of which is associated with amyloid burden, may be a specific imaging marker in early-stage Alzheimer's disease. In this study, this phenomenon was more pronounced in APOE4 noncarriers.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils